Posted on by

Mazdutide and Hepatic Metabolism: Glucagon Co-Agonism, Liver Fat, and Energy Expenditure

3D visualization of dual receptor signaling on a hepatocyte membrane promoting lipid metabolism and mitochondrial oxidation.

Key Takeaways

  • Dual Receptor Engagement: Mazdutide (IBI362) is a synthetic oxyntomodulin analogue that co-activates glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors.
  • Direct Hepatic Action: While hepatocytes lack GLP-1 receptors, abundant hepatic glucagon receptor expression allows mazdutide to directly stimulate fatty acid oxidation and suppress lipogenesis.
  • Substantial Liver Fat Clearance: Clinical imaging using magnetic resonance imaging proton density fat fraction (MRI-PDFF) demonstrates up to an 80% relative reduction in liver fat content across clinical trials.
  • Elevated Energy Expenditure: Glucagon receptor signaling promotes energy expenditure and thermogenesis, countering the metabolic slowdown often observed during caloric restriction.
  • Investigational Status: Developed primarily in China by Innovent Biologics and Eli Lilly, mazdutide has advanced through Phase 3 trials for obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), but is not approved by the United States Food and Drug Administration (FDA).

What Is Mazdutide?

Mazdutide (research code IBI362 or LY3305677) is an investigational peptide designed to mimic mammalian oxyntomodulin, an endogenous gut-derived peptide secreted by enteroendocrine L-cells in response to nutrient ingestion. Unlike selective single-target incretin mimetics such as semaglutide, mazdutide is engineered with balanced dual agonism toward both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR).

The metabolic rationale behind co-agonism is synergistic complementarity. GLP-1 receptor activation is well-established for slowing gastric motility, suppressing appetite in the central nervous system, and augmenting glucose-dependent insulin secretion. Conversely, glucagon receptor activation acts predominantly on the liver and peripheral tissues to stimulate lipid catabolism and elevate basal energy expenditure. By pairing these two distinct physiological pathways into a single molecule, researchers aim to harness glucagon’s metabolic and hepatic clearing actions while using GLP-1 signaling to restrain glucagon-mediated hepatic glucose output.

Mechanism of Action: Glucagon Co-Agonism and Hepatic Metabolism

The metabolic consequences of mazdutide depend on tissue-specific receptor distributions and downstream signaling cascades.

Direct Hepatocyte Signaling

A central limitation of isolated GLP-1 receptor agonists in liver biology is that hepatocytes do not express classical GLP-1 receptors in significant amounts. Any hepatic fat reductions seen with selective GLP-1 agonists occur primarily as secondary downstream effects of systemic weight loss and reduced peripheral caloric intake.

In contrast, the liver is the primary physiological target of glucagon. When mazdutide binds to hepatic GCGR, it stimulates adenylate cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). This intracellular pathway drives several distinct metabolic shifts:

  • Upregulation of Beta-Oxidation: Glucagon signaling enhances the expression and activity of carnitine palmitoyltransferase-1 (CPT-1), facilitating the transport of long-chain fatty acids into mitochondria for beta-oxidation.
  • Ketogenesis Promotion: The enhanced flux of fatty acid oxidation produces acetyl-CoA, elevating circulating ketone bodies such as beta-hydroxybutyrate, which serves as a biomarker of direct hepatic lipid utilization.
  • Downregulation of De Novo Lipogenesis: Glucagon-induced phosphorylation inactivates acetyl-CoA carboxylase (ACC) and downregulates sterol regulatory element-binding protein 1c (SREBP-1c), suppressing the enzymatic creation of new triglycerides within liver tissue.

Balancing Glycemia and Energy Expenditure

Historically, therapeutic activation of the glucagon receptor raised concerns regarding hyperglycemia, because glucagon promotes glycogenolysis and gluconeogenesis. In mazdutide, the co-formulated GLP-1 receptor activity counteracts this effect by enhancing glucose-dependent insulin release from pancreatic beta cells, thereby keeping fasting plasma glucose and glycated hemoglobin (HbA1c) tightly regulated.

Simultaneously, glucagon agonism increases resting energy expenditure (REE). In preclinical and clinical studies of oxyntomodulin analogues, glucagon signaling induces thermogenic programs and increases caloric burn, providing a metabolic countermeasure against the compensatory drop in resting metabolic rate that typically accompanies sustained dietary calorie restriction.

Clinical Evidence: Liver Fat Reduction and MASLD

Clinical trials investigating mazdutide have increasingly incorporated non-invasive imaging techniques to measure hepatic steatosis directly, most notably magnetic resonance imaging proton density fat fraction (MRI-PDFF).

Findings from the GLORY Trial Series

In the pivotal Phase 3 GLORY-1 trial (NCT05607680) evaluating mazdutide in adults with overweight or obesity, an exploratory subgroup of participants underwent serial MRI-PDFF measurements. Over a 48-week period, investigators observed profound, dose-dependent reductions in liver fat content:

  • Participants receiving the 6 mg dose with elevated baseline liver fat (≥10%) achieved an average relative liver fat content reduction of 80.2%.
  • A significant proportion of participants with baseline steatosis achieved complete normalization of liver fat (defined as MRI-PDFF <5%) by the end of the trial.
  • Concomitant decreases occurred in circulating liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), reflecting reduced hepatocellular stress and liver inflammation.

The dedicated GLORY-3 study (NCT06884293) was designed to compare mazdutide (9 mg) directly against the selective GLP-1 receptor agonist semaglutide (2.4 mg) in individuals with obesity accompanied by metabolic dysfunction-associated fatty liver disease (MAFLD/MASLD), testing whether dual agonism delivers superior liver fat clearance relative to pure GLP-1 agonism.

Phase 2 Steatosis and Biomarker Evaluations

Phase 2 data presented at major hepatology congresses revealed that in participants with MASLD and baseline liver fat ≥5%, weekly mazdutide administration resolved steatosis in over 60% of participants by week 32 and over 70% by week 48 at higher dosage tiers (10 mg and 16 mg equivalents). Alongside imaging results, trial participants demonstrated marked improvements in the homeostatic model assessment of insulin resistance (HOMA2-IR), serum triglycerides (declining by >30%), and total cholesterol.

Safety Findings and Research Limitations

While the metabolic profile of mazdutide shows significant potency, the compound carries notable safety considerations and research limitations.

Adverse Events Profile

The most common adverse events associated with mazdutide mirror the incretin class, driven largely by GLP-1 receptor activation on the gastrointestinal tract. These include:

  • Nausea, vomiting, diarrhea, and constipation, which are generally mild to moderate and peak during dose titration.
  • Dose-dependent increases in resting heart rate, an established on-target effect of both GLP-1 and glucagon receptor stimulation in cardiac tissue.
  • Decreased appetite leading to reduced total food intake.

Evidence Gaps

Several crucial research questions remain unanswered:

  • Histological Endpoints: Most available liver data rely on non-invasive MRI-PDFF imaging. Although liver fat reduction strongly correlates with disease improvement, randomized trials with paired liver biopsies are necessary to evaluate histological resolution of metabolic dysfunction-associated steatohepatitis (MASH) and regression of liver fibrosis.
  • Demographic Generalizability: The vast majority of Phase 2 and Phase 3 trial data for mazdutide have been conducted in Chinese clinical cohorts. Global multi-ethnic studies are required to establish whether pharmacokinetics, efficacy, and tolerability profiles translate identically across diverse patient populations.
  • Long-Term Cardiovascular and Hepatic Safety: Long-term cardiovascular outcome trials (CVOTs) are still required to assess the chronic safety of sustained glucagon agonism on cardiac rhythm, blood pressure, and lean muscle mass preservation.

Regulatory Status

Mazdutide is an investigational drug and is not approved by the US FDA or the European Medicines Agency (EMA). In China, Innovent Biologics submitted New Drug Applications (NDAs) to the National Medical Products Administration (NMPA) for weight management and type 2 diabetes indications following positive Phase 3 GLORY and DREAMS readouts. At present, it remains restricted to authorized clinical trials and laboratory research protocols.

Frequently Asked Questions

How does mazdutide differ from selective GLP-1 receptor agonists?

Selective GLP-1 receptor agonists act solely on the GLP-1 receptor, reducing appetite, slowing gastric emptying, and stimulating insulin. Mazdutide is a dual agonist targeting both GLP-1 and glucagon receptors. This allows mazdutide to directly activate hepatic lipid oxidation pathways and increase resting energy expenditure, mechanisms not directly stimulated by GLP-1 alone.

Why does glucagon activation not cause high blood sugar with mazdutide?

Although isolated glucagon promotes hepatic glucose release, the co-agonism with GLP-1 balances this effect. GLP-1 signaling stimulates pancreatic insulin secretion in a glucose-dependent manner and reduces caloric intake, which neutralizes the hyperglycemic potential of glucagon while preserving its lipid-clearing and thermogenic properties.

What is MRI-PDFF, and why is it used in mazdutide trials?

Magnetic resonance imaging proton density fat fraction (MRI-PDFF) is a quantitative, non-invasive imaging biomarker that measures the percentage of triglyceride content within the liver. It provides an accurate, reproducible assessment of hepatic steatosis without the risks associated with invasive liver biopsies, making it the primary objective endpoint in early-to-mid phase MASLD studies.

Is mazdutide approved for personal weight loss or fatty liver treatment?

No. Mazdutide is not approved by the FDA or EMA for any clinical indication. It remains an investigational research peptide under clinical and regulatory evaluation.

References

Research Summary

Mazdutide demonstrates strong mechanistic rationale and robust Phase 2 and Phase 3 clinical trial evidence for reducing hepatic steatosis, enhancing energy expenditure, and promoting systemic weight loss. By combining GLP-1 receptor-driven appetite control with glucagon receptor-mediated hepatic fatty acid oxidation, the peptide achieves direct liver fat clearance of up to 80% on MRI-PDFF assessments. However, the current evidence base is predominantly centered within Chinese clinical trial populations, and data assessing long-term histological liver fibrosis reversal remain incomplete. Mazdutide is an investigational agent without FDA approval, and further global studies are required to define its long-term hepatic and cardiovascular safety profile.